NEW YORK, Oct. 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=107512&from=4 CLASS PERIOD: This lawsuit is on beha ...

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Metagenomi investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between F ...

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased stock pursuant to and/or traceable to Metagenomi Inc.'s (NASDAQ: MGX) registration statement for the initial public offering (IPO) held between February 9 and 13, 2024. Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. For more information, ...

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=107041&from=3 CLASS PERIOD: This lawsuit is on ...

Core Viewpoint - A securities class action lawsuit has been filed against Metagenomi Inc. for allegedly misleading investors regarding its business prospects and relationship with Moderna during the specified class period [1][5]. Company Overview - Metagenomi Inc. is a genetic medicines company based in Emeryville, CA, with a significant collaboration with Moderna, a leading Covid-19 vaccine company [3]. - The collaboration included a Strategic Collaboration and License Agreement established on October 29, 2021, which involved multiple four-year research programs [3]. Key Events - On May 1, 2024, Metagenomi announced the mutual termination of its collaboration agreement with Moderna, which was a critical aspect of its business strategy [4]. - Following the announcement, Metagenomi's share price dropped from $7.04 to $6.17 within a day and continued to decline, trading slightly above $2.00 at the time of the lawsuit filing [4]. Legal Proceedings - The lawsuit claims that Metagenomi and its senior executives misled investors about the company's prospects, particularly concerning its relationship with Moderna [5]. - Investors who purchased Metagenomi securities during the class period can seek to be appointed as lead plaintiff representatives by November 25, 2024 [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Company Overview - Metagenomi, Inc. is described as a "genetic medicines company" that had a collaboration with Moderna, a leading Covid-19 vaccine company [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [4] Group 2: Legal Proceedings - A class action lawsuit has been filed against Metagenomi following the announcement on May 1, 2024, that the collaboration agreement with Moderna was mutually terminated [4] - Investors are encouraged to join the class action and can do so without any out-of-pocket fees through a contingency fee arrangement [1][2] Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked highly for securities class action settlements [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 07, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Metagenomi Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) investors of a class action representing investors that bought securities between February 9 and February 13, 2024, inclusive (the "Class Period"). Metagenomi investors have until November 25, 2024 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F ...

Group 1 - The Law Offices of Howard G. Smith announced a securities fraud class action lawsuit against Metagenomi, Inc. for investors with substantial losses since the company's IPO in February 2024 [1] - The lawsuit alleges that Metagenomi failed to disclose that its collaboration with Moderna would terminate in the immediate future, which misled investors regarding the company's business prospects [2] - Investors are encouraged to contact the law firm to discuss their legal rights and options regarding the class action [3]

NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=106647&from=4 CLASS PERIOD: This lawsuit is on behal ...

Core Viewpoint - The article discusses a class action lawsuit against Metagenomi, Inc. following its IPO, highlighting the deadline for investors to file a lead plaintiff motion and the alleged misleading statements made by the company regarding its collaboration with Moderna [1][4]. Group 1: Company Overview - Metagenomi, Inc. conducted its IPO on February 13, 2024, selling approximately 6.25 million shares at $15 per share [3]. - Following the announcement of the termination of its collaboration with Moderna on May 1, 2024, Metagenomi's stock price dropped by $0.87, or 12.4%, closing at $6.17 per share on May 2, 2024 [3]. Group 2: Legal Proceedings - A class action lawsuit has been filed on behalf of investors who purchased Metagenomi securities during the IPO, with a deadline of November 25, 2024, to file a lead plaintiff motion [1][6]. - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, particularly regarding the collaboration with Moderna [4].